RGNX Quote, Financials, Valuation and Earnings

CytomX Therapeutics, Inc. has a net margin of -208.32% compared to REGENXBIO, Inc.'s net margin of -238.62%. REGENXBIO, Inc.'s return on equity of -73.5% beat CytomX Therapeutics, Inc.'s return on equity of 61.33%.

REGENXBIO, Inc. has a consensus price target of $29.18, signalling upside risk potential of 258.5%. On the other hand CytomX Therapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 65.75%. Given that REGENXBIO, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe REGENXBIO, Inc. is more attractive than CytomX Therapeutics, Inc..

REGENXBIO, Inc. has a beta of 1.052, which suggesting that the stock is 5.23% more volatile than S&P 500. In comparison CytomX Therapeutics, Inc. has a beta of 2.444, suggesting its more volatile than the S&P 500 by 144.417%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. CytomX Therapeutics, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $29.7M, which are larger than CytomX Therapeutics, Inc. quarterly revenues of $6M. REGENXBIO, Inc.'s net income of -$61.9M is lower than CytomX Therapeutics, Inc.'s net income of -$14.2M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while CytomX Therapeutics, Inc.'s PE ratio is 12.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.58x versus 5.51x for CytomX Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -208.32% compared to REGENXBIO, Inc.'s net margin of 47.99%. REGENXBIO, Inc.'s return on equity of -73.5% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

REGENXBIO, Inc. has a consensus price target of $29.18, signalling upside risk potential of 258.5%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $306.56 which suggests that it could grow by 17.1%. Given that REGENXBIO, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe REGENXBIO, Inc. is more attractive than Krystal Biotech, Inc..

REGENXBIO, Inc. has a beta of 1.052, which suggesting that the stock is 5.23% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $29.7M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. REGENXBIO, Inc.'s net income of -$61.9M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 38.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.58x versus 20.13x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of -208.32% compared to REGENXBIO, Inc.'s net margin of --. REGENXBIO, Inc.'s return on equity of -73.5% beat Omeros Corp.'s return on equity of --.

REGENXBIO, Inc. has a consensus price target of $29.18, signalling upside risk potential of 258.5%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 215.62%. Given that REGENXBIO, Inc. has higher upside potential than Omeros Corp., analysts believe REGENXBIO, Inc. is more attractive than Omeros Corp..

REGENXBIO, Inc. has a beta of 1.052, which suggesting that the stock is 5.23% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.446, suggesting its more volatile than the S&P 500 by 144.588%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $29.7M, which are larger than Omeros Corp. quarterly revenues of --. REGENXBIO, Inc.'s net income of -$61.9M is lower than Omeros Corp.'s net income of -$21.2M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.58x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -208.32% compared to REGENXBIO, Inc.'s net margin of -45.06%. REGENXBIO, Inc.'s return on equity of -73.5% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

REGENXBIO, Inc. has a consensus price target of $29.18, signalling upside risk potential of 258.5%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 13.53%. Given that REGENXBIO, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe REGENXBIO, Inc. is more attractive than Sarepta Therapeutics, Inc..

REGENXBIO, Inc. has a beta of 1.052, which suggesting that the stock is 5.23% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $29.7M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. REGENXBIO, Inc.'s net income of -$61.9M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.58x versus 0.81x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.